Back to top
more

Beam Therapeutics (BEAM)

(Delayed Data from NSDQ)

$28.33 USD

28.33
1,245,014

-1.43 (-4.81%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $28.57 +0.24 (0.85%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ekta Bagri headshot

Three Genomics Stocks Worth Tracking This Year

by Ekta Bagri

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

Kanishka Das headshot

Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?

by Kanishka Das

Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.

Zacks Equity Research

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?

by Zacks Equity Research

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kanishka Das headshot

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

by Kanishka Das

Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.

Sundeep Ganoria headshot

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

by Sundeep Ganoria

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

Kanishka Das headshot

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

by Kanishka Das

Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.

Kanishka Das headshot

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

by Kanishka Das

Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.

Zacks Equity Research

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

by Zacks Equity Research

RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.

Zacks Equity Research

Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up

by Zacks Equity Research

MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.